戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es for the development of an affordable anti-Chagasic agent.
2 may facilitate the development of novel anti-Chagasic agents.
3                 The oxidative stress in both chagasic animals and animals with ethanol-induced cardio
4                     Thus, NA restores Ito in chagasic canine epicardial myocytes.
5                                              Chagasic cardiomyopathy (CC) is the most frequent nonisc
6 may provide insight into the pathogenesis of chagasic cardiomyopathy and provide new targets for inte
7 cruzi, is a leading cause of heart disease ("chagasic cardiomyopathy") in Latin America, disproportio
8 intracellular protozoan parasite that causes Chagasic cardiomyopathy, elicits a robust hypertrophic r
9  Patients 18 to 75 years of age with chronic chagasic cardiomyopathy, New York Heart Association clas
10                                      Chronic chagasic cardiomyopathy, the most devastating manifestat
11 ic oxide synthase (iNOS) expression in acute Chagasic cardiomyopathy, we studied a rat model of acute
12 soma cruzi is the causative agent of chronic chagasic cardiomyopathy.
13  or quality of life in patients with chronic chagasic cardiomyopathy.
14  randomized trial of BMNC therapy in chronic chagasic cardiomyopathy.
15 s (BMNCs) improves heart function in chronic chagasic cardiomyopathy.
16 anges in the myocardium of a murine model of chagasic cardiomyopathy.
17 derived ET-1, in the pathogenesis of chronic Chagasic cardiomyopathy.
18 ested as contributing to the pathogenesis of Chagasic cardiomyopathy.
19 f pathways involved in cardiac remodeling in chagasic cardiomyopathy.
20  participate in the pathophysiology of acute Chagasic cardiomyopathy.
21 ents at different clinical stages of chronic chagasic heart disease.
22 its parasite proliferation but may result in chagasic heart disease.
23 dative stress-induced injurious processes in chagasic heart dysfunction.
24  production, and energy homeostasis in acute chagasic hearts.
25  of conventional HF therapies, patients with Chagasic HF with reduced ejection fraction continue to h
26                 There were 195 patients with Chagasic HF with reduced ejection fraction, 1300 with ot
27 re significantly reduced in TcVac2-immunized chagasic mice.
28 ontrol of parasite burden and myocarditis in chagasic mice.
29 abolic decay and energy homeostasis in acute chagasic myocarditis and further suggest that oxidative
30 results suggest that the reduction of Ito in chagasic myocytes during the acute stage of Chagas' dise
31 7.2, 12.5, and 11.4 per 100 person-years for Chagasic, other nonischemic, and ischemic patients, resp
32 tigator-reported etiology was categorized as Chagasic, other nonischemic, or ischemic cardiomyopathy.
33 , bears primary responsibility for producing chagasic pathology.
34                                      Chronic chagasic patients (CCPs) have dysfunctional CD8(+) T cel
35              Compared with other etiologies, Chagasic patients were more often female, younger, and h
36 evels of IL-7 were also increased in chronic chagasic patients.
37 esence of the parasite in the bloodstream of chagasic patients.
38 contributed to declining cardiac function in chagasic rats.
39 function was prevented in PBN +/- BZ-treated chagasic rats.
40 ative pathology and chronic heart failure in chagasic rats.
41 multispecific high-affinity IgG from chronic chagasic sera and on sodium dodecyl sulfate-polyacrylami
42 confidence interval, 1.15-1.94; P=0.003) and Chagasic versus ischemic: 1.55 (1.18-2.04; P=0.002).
43 ents, respectively-adjusted hazard ratio for Chagasic versus other nonischemic: 1.49 (95% confidence

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。